New orally active proteasome inhibitors in multiple myeloma

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 1-9

  Allegra, Alessandro ^a   Alonci, Andrea ^a   Gerace, Demetrio ^a   Russo, Sabina ^a   Innao, Vanessa ^a   Calabrò, Laura ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bortezomib; Carfilzomib; Delanzomib; Ixazomib; Marizomib; Multiple myeloma; Oral administration; Proteasome inhibitor; Therapy

Indexed keywords

5 AMINO 8 HYDROXYQUINOLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CARFILZOMIB; CASPASE 8; CHLOROQUINE; CINNABARAMIDE DERIVATIVE; CLIOQUINOL; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; OPROZOMIB; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ACTINOBACTERIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHENIA; BALANCE DISORDER; BINDING AFFINITY; BOLUS INJECTION; CANCER RESISTANCE; CANCER SURVIVAL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONSTIPATION; CRYSTAL STRUCTURE; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HUMAN; IC 50; INSOMNIA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SALINISPORA TROPICA; SKIN TOXICITY; STOMATITIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; TOXICITY TESTING; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84890552098     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.018     Document Type: Review

References (84)

1. Lois L.M., Lima C.D. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J 2005, 24:439-451.
2. Smith D.M., Chang S.-C., Park S., Finley D., Cheng Y., Goldberg A.L. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's α ring opens the gate for substrate entry. Mol Cell 2007, 27:731-744.
3. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
4. Marques A.J., Palanimurugan R., Matias A.C., Ramos P.C., Dohmen R.J. Catalytic mechanism and assembly of the proteasome. Chem Rev 2009, 109:1509-1536.
5. Orlowski R.Z., Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14:1649-1657.
6. Glickman M.H., Rubin D.M., Coux O., Wefes I., Pfeifer G., Cjeka Z., et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 1998, 94:615-623.
7. Gentile M., Recchia A.G., Mazzone C., Lucia E., Vigna E., Morabito F. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013, [Epub ahead of print].
8. McBride A., Ryan P.Y. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2013, 13:339-358.
9. Shah J.J., Orlowski R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23:1964-1979.
10. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., et al. Multicenter phase II study of Bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
11. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007, 67:1783-1792.
12. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., et al. Potent activity of Carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110(9):3281-3290.
13. Siegel D., Martin T., Nooka A., Harvey R.D., Vij R., Niesvizky R., et al. Integrated safety profile of single-agent Carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica 2013, [Epub ahead of print].
14. Dick L.R., Fleming P.E. Building on Bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
15. Genin E., Reboud-Ravaux M., Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010, 10:232-256.
16. Ruggeri B., Miknyoczki S., Dorsey B., Hui A.M. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Adv Pharmacol 2009, 57:91-135.
17. Groll M., Potts B.C. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr Top Med Chem 2011, 11:2850-2878.
18. Mincer T.J., Jensen P.R., Kauffman C.A., Fenical W. Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. Appl Environ Microbiol 2002, 68:5005-5011.
19. Maldonado L., Fenical W., Jensen P.R., Kauffman C.K., Mincer T.J., Ward A.C., et al. Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int J Syst Evol Microbiol 2005, 55:1759-1766.
20. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 2003, 42:355-357.
21. Groll M., Huber R., Potts B.C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006, 128:5136-5141.
22. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
23. Lawasut P., Chauhan D., Laubach J., Hayes C., Fabre C., Maglio M., et al. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep 2012, 7:258-266.
24. Macherla V.R., Mitchell S.S., Manam R.R., Reed K.A., Chao T.H., Nicholson B., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005, 48:3684-3687.
25. Chauhan D., Hideshima T., Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006, 95:961-965.
26. Manam R.R., McArthur K.A., Chao T.H., Weiss J., Ali J.A., Palombella V.J., et al. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J Med Chem 2008, 51:6711-6724.
27. Miller C.P., Manton C., Hale R., DeBose L.K., Macherla V.R., Potts B.C., et al. Specific and prolonged proteasome inhibition dictates apoptosis induction by Marizomib and its analogs. Chem Biol Interact 2011, 194:58-68.
28. Obaidat A., Weiss J., Wahlgren B., Manam R.R., Macherla V.R., McArthur K., et al. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition attenuated efflux, and greater. Cytotoxicity than its reversible analogs. JPET 2011, 337:479-486.
29. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
30. Fenical W.H., Jensen P.R., Palladino M.A., Lam K.S., Lloyd G.K., Potts B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009, 17:2175-2180.
31. Lam K.S., Lloyd G.K., Neuteboom S.T.C., Palladino M.A., Sethna K.M., Spear M.A., et al. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. Natural Products Chemistry for Drug Discovery 2010, 355-373. Royal Society of Chemistry, Cambridge, UK, [RSC Biomolecular Sciences No. 18]. A.D. Buss, M.S. Butler (Eds.).
32. Ruiz S., Krupnik Y., Keating M., Chandra J., Palladino M., McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than Bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006, 5:1836-1843.
33. Miller C.P., Rudra S., Keating M.J., Wierda W.G., Palladino M., Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009, 113:4289-4299.
34. Cusack J.C., Liu R., Xia L., Chao T.H., Pien C., Niu W., et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006, 12:6758-6764.
35. Singh A.V., Palladino M.A., Lloyd G.K., Potts B.C., Chauhan D., Anderson K.C. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (Marizomib) in a human plasmacytoma. Br J Haematol 2010, 149:550-559.
36. Richardson P.G., Spencer A., Cannell P. Phase 1 clinical evaluation of twice-weekly Marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annu Meet Abstr Blood 2011, 118:140-141. [Abstr. 302].
37. Millward M., Spear M.A., Townsend A., Sweeney C., Sukumaran S., Longenecker A., et al. Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic and lung cancer. Mol Cancer Ther; Meet Abstr Supple 2009, 8. [Abstr. 107].
38. Townsend A.R., Millward M., Price T., Mainwaring P., Spencer A., Longenecker A., et al. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (Advanced Malignancies Arm). J Clin Oncol 2009, 27:15s.
39. Hamlin P.A., Aghajanian C., Younes A., Hong D.S., Palladino M.A., Longenecker A.M., et al. First-in-human phase 1 study of the novel structure proteasome inhibitor NPI-0052. J Clin Oncol 2009, 27:15s.
40. Potts B.C., Lam K.S. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide A (Marizomib) and other salinosporamides. Mar Drugs 2010, 8:835-880.
41. Ling T., Potts B.C., Macherla V.R. Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy. J Org Chem 2010, 75:3882-3885.
42. 3-strain enabled retention of chirality during bis-cyclization of β-ketoamides: total synthesis of (-)-salinosporamide A and (-)-homosalinosporamide A. Chem Commun (Camb) 2010, 46:4803-4805.
43. Potts B.C., Albitar X.M., C Anderson K.C., Baritaki S., Berkers C., Bonavida B., et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011, 11:254-284.
44. Bross P.F., Kane R., Farrell A.T., Abraham S., Benson K., Brower M.E., et al. Approval summary for Bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004, 10:3954-3964.
45. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
46. Chauhan D., Singh A., Brahmandam M., Podar K., Hideshima T., Richardson P., et al. Combination of proteasome inhibitors Bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
47. Roccaro A.M., Leleu X., Sacco A., Jia X., Melhem M., Moreau A.S., et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008, 111:4752-4763.
48. Sloss C.M., Wang F., Liu R., Xia L., Houston M., Ljungman D., et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008, 14:5116-5123.
49. Baritaki S., Suzuki E., Umezawa K., Spandidos D.A., Berenson J., Daniels T.R., et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008, 180:6199-6210.
50. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., Palladino M.A., Anderson K.C. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115:834-845.
51. Millward M., Price T., Townsend A., Sweeney C., Spencer A., Sukumaran S., et al. Phase 1 clinical trial of the novel proteasome inhibitor Marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012, 30:2303-2317.
52. Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M., Berger A., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70:1970-1980.
53. Gupta N., Saleh M., Venkatakrishnan K. Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies. ASH Annu Meeting Abstr Blood 2011, 118:1433.
54. Assouline S., Chang J., Rifkin R. MLN9708, a novel, investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma: results of a phase 1 dose-escalation study. ASH Annu Meeting Abstr Blood 2011, 118:2672.
55. Lee E.C., Fitzgerald M., Bannerman B., Donelan J., Bano K., Terkelsen J.P., et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011, 17:7313-7323.
56. Chauhan D., Tian Z., Zhou B., Kuhn D., Orlowski R., Raje N., et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011, 17:5311-5321.
57. Tian Z., Zhao J.J., Tai Y.T., Amin S.B., Hu Y., Berger A.J., et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012, 120:3958-3967.
58. Kumar S., Bensinger W.I., Reeder C.B. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study. ASH Annu Meeting Abstr Blood 2011, 118:816.
59. Richardson P.G., Baz R., Wang L. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study. ASH Annu Meeting Abstr Blood 2011, 118:301.
60. Appel A. More shots on target. Nature 2011, 480:40.
61. Berdeja J.G., Richardson P.G., Lonial S. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annu Meeting Abstr Blood 2011, 118:479.
62. Zhou H.J., Aujay M.A., Bennett M.K., Dajee M., Demo S.D., Fang Y., et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009, 52:3028-3038.
63. Chauhan D., Singh A.V., Aujay M., Kirk C.J., Bandi M., Ciccarelli B., et al. A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116:4906-4915.
64. Zang Y., Thomas S.M., Chan E.T., Kirk C.J., Freilino M.L., DeLancey H.M., et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res 2012, 18:5639-5649.
65. Hurchla M.A., Garcia-Gomez A., Hornick M.C., Ocio E.M., Li A., Blanco J.F., et al. The epoxyketone-based proteasome inhibitors Carfilzomib and orally bioavailable Oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013, 27:430-440.
66. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with Bortezomib. Blood 2008, 111:2765-2775.
67. Sala F., Marangon E., Bagnati R., Livi V., Cereda R., D'Incalci M., et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. J Mass Spectrom 2010, 45:1299-1305.
68. Dorsey B.D., Iqbal M., Chatterjee S., Menta E., Bernardini R., Bernareggi A., et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008, 51:1068-1072.
69. Sanchez E., Li M., Steinberg J.A., Wang C., Shen J., Bonavida B., et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of Bortezomib and melphalan. Br J Haematol 2010, 148:569-581.
70. Gallerani E., Zucchetti M., Brunelli D., Marangon E., Noberasco C., Hess D., et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2013, 49:290-296.
71. Ocio E.M., Mateos M.V., San-Miguel J.S. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opin Investig Drugs 2012, 21:1075-1087.
72. Sanchez E., Li M., Li J., Wang C., Chen H., Jones-Bolin S., et al. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res 2012, 36:1422-1427.
73. Sprangers R., Li X., Mao X., Rubinstein J.L., Schimmer A.D., Kay L.E. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry 2008, 47:6727-6734.
74. Li X., Wood T.E., Sprangers R., Jansen G., Franke N.E., Mao X., et al. Effect of noncompetitive proteasome inhibition on Bortezomib resistance. J Natl Cancer Inst 2010, 102:1069-1082.
75. Richards D.A. Prophylactic value of clioquinol against travellers' diarrhoea. Lancet 1971, 1:44-45.
76. Woodward W.E., Rahman A.S. Trial of clioquinol in cholera. Lancet 1969, 2:270.
77. Chen D., Cui Q.C., Yang H., Barrea R.A., Sarkar F.H., Sheng S., et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 2007, 67:1636-1644.
78. Daniel K.G., Chen D., Orlu S., Cui Q.C., Miller F.R., Dou Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005, 7:R897-R908.
79. Mao X., Li X., Sprangers R., Wang X., Venugopal A., Wood T., et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia 2009, 23:585-590.
80. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome Bortezomib resistance. J Natl Cancer Inst 2011, 103:1007-1017.
81. Rachid S., Huo L., Herrmann J., Stadler M., Köpcke B., Bitzer J., et al. Mining the cinnabaramide biosynthetic pathway to generate novel proteasome inhibitors. Chembiochem 2011, 12:922-931.
82. Arastu-Kapur S., Anderl J.L., Kraus M., Parlati F., Shenk K.D., Lee S.J., et al. Nonproteasomal targets of the proteasome inhibitors Bortezomib and Carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011, 17(9):2734-2743.
83. Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 2012, 49:S33-S46.
84. Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med 2012, 18:7.